Letter to Industry Canada re: Addition of oseltamivir phosphate to Schedule 1 to the Patent Act
“On July 1, 2006 the Departments of Industry and Health published, in Part I of the Canada Gazette, the proposed text of an order to amend Schedule 1 to the Patent Act to add “oseltamivir phosphate”, in both capsule form as well as in powder for oral suspension, to the list of patented pharmaceutical products … Read more